QB3@953 Companies Attract $1.36B In Capital

One Bench at a Time

QB3@953 Companies Attract $1.36B In Capital

San Francisco, CA, May 1, 2017 – QB3@953 proved definitively that its incubator facilities allow life science startups to progress at lightening speed, making a huge impact on the life-science ecosystem of the Bay Area.

QB3@953 tenant and alumni companies are thriving. In the three short years since its founding, QB3@953 companies attracted $1.36Bn in investments and acquisitions.

Clearly, QB3@953 is fulfilling its mission of “enabling awesome”. Renting small units of space in a state-of-the-art biolab facility also allows a more diverse set of entrepreneurs the chance to become great. For instance, of the 94 resident and alumni companies, 11 of them are lead by women, a much higher percentage than in the industry as a whole.

The incubator building in San Francisco’s Dogpatch neighborhood supports 35-45 ambitious startups, providing them lab space, connecting them with venture funding, and offering business services. Most businesses outgrow and “graduate” from the incubator into their own lab within two years, but remain part of the QB3@953 family.

“QB3@953 has had remarkable success in attracting the best entrepreneurial scientists,” said Doug Crawford, General Manager. “We are proud to have been able to help them achieve so much in such a short time.”

Crawford also points out that this constellation of exciting startups has attracted support from an ever growning set of partners that includes J&J, Amgen, GSK, Pfizer, L’Oreal and Servier. “We provide an opportunity for the largest and smallest companies to work together – ensuring that the startups are focused on the most important quesitons and accelerating early collaborations,” says Crawford.

MEDIA CONTACTS

Douglas Crawford, General Manager
Ph: 415-205-4825
Douglas.Crawford@missionbaycapital.com

qb3at953 News

Upcoming Event

  • Capitalizing on New Trends of Chinese Investments in the U.S. and Navigating Legal Issues for Startups in China

    12:30-13:30
    01/23/2018
    Karen Wong, PhD, Partner Wilson Sonsini Goodrich & Rosati RSVP The rapid growth of the healthcare market in China is fueling many Chinese funds and pharmaceutical companies to invest in healthcare companies in the US and to attract talent to set up companies in China. This presents an unprecedented cross-border environment and new business opportunities for Bay Area entrepreneurs. Please join us for a lively and hands-on discussion with Dr. Karen Wong, a partner of Wilson Sonsini Goodrich & Rosati, to learn about real-life stories, opportunities, and pitfalls in setting up startups with planned growth or commercialization in China. Karen will cover the topics of US-China cross-border deal structures, technology transfer and licensing, fundraising and term-sheet negotiation, and patent filing strategies for both the US and China markets. Dr. Karen Wong has a wealth of experience in life sciences patent preparation and prosecution, technology transfer and licenses, and due-diligence studies in connection with VC financing, M&A, and public offering. Dr. Karen Wong has served as IP counsel to many venture-backed companies in the US and in China, and has worked on numerous major cross-border transactions, strategic alliance transactions, acquisitions, spin-outs, and IPOs. Karen is fluent in Mandarin, Cantonese, and Sichuan dialect.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter